Statistical Approaches to Establishing Bioequivalence
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
February 1, 2001
April 29, 2020
3391de1a-8097-49d5-83f8-195b2013a5e2
Related Documents
Changes to an Approved NDA or ANDA: Questions and Answers: Guidance for Industry
Guidance DocumentJanuary 1, 2001Center for Drug Evaluation and Research
Alternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs: Guidance for Industry
Guidance DocumentDecember 1, 2000Center for Drug Evaluation and Research
Integration of Dose-Counting Mechanisms into MDI Drug Products
Guidance DocumentMarch 13, 2003Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.